IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity [preprint]
Yilmaz, Nese Kurt
Toomey, Jacqueline R.
Klempner, Mark S.
Schiffer, Celia A.
UMass Chan AffiliationsSchiffer Lab
Department of Biochemistry and Molecular Pharmacology
Amino Acids, Peptides, and Proteins
Immunology of Infectious Disease
Immunoprophylaxis and Therapy
MetadataShow full item record
AbstractCOVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
Ejemel M, Li Q, Hou S, Schiller ZA, Wallace AL, Amcheslavsky A, Yilmaz NK, Toomey JR, Schneider R, Close BJ, Chen DY, Conway HL, Mohsan S, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. bioRxiv [Preprint]. 2020 May 15:2020.05.15.096719. doi: 10.1101/2020.05.15.096719. PMID: 32511396; PMCID: PMC7263543. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/29495
Full author list omitted for brevity. For the full list of authors, see article.